Evidence Explorer

Search covers the whole site. For a focused route, choose an index below.

Start with your question

Two ways to use the collection

Start Here: a practical guide to data analysis and critical scientific thinking →

New in the repository

Sixteen source-linked briefs extend the collection into commonly searched natural-product claims, supportive care and documented risks.

Follow the evidence, including when it disappoints

Evidence Updates

See the dated record of new entries, revisions, safety changes and coverage limits on the Evidence Updates page.

Added October 14, 2026

Ten new clinical-question records broaden the nutrition, supportive-care and cancer-control coverage. Three records document important null cancer-control findings, and the high-dose vitamin D record transparently places the new phase III result beside the earlier phase II signal.

• Individualized dietary counseling during radiotherapy — positive randomized signal / practical guidance.
• Neutropenic diets during leukemia treatment and stem-cell transplant — no demonstrated infection-prevention benefit.
• Soy foods after breast cancer — observationally reassuring; whole foods are not isoflavone supplements.
• Perioperative immunonutrition for gastrointestinal cancer surgery — positive randomized signal, formulation-specific.
• High-dose vitamin D with chemotherapy for metastatic colorectal cancer — phase III found no progression-free or overall-survival benefit.
• High-vegetable diet during prostate-cancer active surveillance — no demonstrated progression benefit despite changed eating behavior.
• Selenium during pelvic radiotherapy — small randomized diarrhea signal limited to documented deficiency and supervised dosing.
• Photobiomodulation for oral mucositis — positive randomized mucositis signal, protocol-specific.
• Self-acupressure for persistent fatigue after breast cancer — positive randomized fatigue signal; symptom support, not cancer treatment.
• Pomegranate products for prostate-cancer progression — placebo-controlled studies did not demonstrate cancer-control benefit.

Added October 15, 2026

Ten botanical and nutraceutical clinical-question records add negative, mixed, positive and harmful findings. The strongest safety signal is the stopped GENIUS phase III trial of Goshajinkigan, where grade 2 or worse oxaliplatin neuropathy was more frequent with the Kampo formula.

• Black cohosh for hot flashes after breast cancer — phase III found no benefit beyond placebo; liver and product-quality cautions.
• Guarana for cancer-related fatigue — conflicting small trials and heterogeneous meta-analyses.
• Chamomile mouthwash for treatment-related oral mucositis — the largest placebo-controlled trial was negative; smaller later signals remain uncertain.
• Calendula ointment for breast-radiotherapy skin reactions — positive older randomized signal against trolamine, formulation-specific.
• Aloe vera gel for radiation dermatitis — conflicting results across radiation sites and products.
• Vitamin E for hot flashes after breast cancer — about one fewer hot flash per day; benefit was clinically minimal.
• Intravenous glutathione to prevent platinum neuropathy — positive small-trial neuropathy signal, insufficient for routine intravenous use.
• Oral L-glutamine for treatment-related oral mucositis — older negative trials and a large 2026 head-and-neck signal; regimen-specific.
• Milk thistle for chemotherapy-associated liver injury — laboratory trends without demonstrated clinical liver benefit.
• Goshajinkigan to prevent oxaliplatin neuropathy — phase III stopped early; neuropathy was more frequent with the Kampo formula.

Exercise and rehabilitation additions — October 16, 2026

Ten records add functional, cognitive, sleep and cancer-control questions. The collection keeps improvements in symptoms or fitness separate from tumor response.

• Structured physiotherapy after breast-cancer surgery — Positive randomized rehabilitation evidence.
• Exercise prehabilitation before head-and-neck chemoradiotherapy — Preliminary positive randomized signal.
• Supervised exercise during neoadjuvant breast chemotherapy — No demonstrated tumor-response benefit.
• Lesion-aware exercise with prostate-cancer bone metastases — Positive functional and supervised-safety signal.
• Aerobic exercise for cognitive changes during breast-cancer chemotherapy — Mixed randomized evidence.
• Aerobic exercise for neuropathy after ovarian-cancer chemotherapy — Promising secondary randomized signal.
• Manual lymph drainage to prevent arm lymphedema after breast surgery — No demonstrated prevention benefit.
• Preventive swallowing exercises during head-and-neck radiotherapy — Mixed evidence.
• Exercise during allogeneic stem-cell transplantation — Small randomized supportive signal.
• Intermittent aerobic exercise for insomnia during breast-cancer chemotherapy — Primary sleep-duration endpoint negative.

Added October 17, 2026

Ten structured mind–body, sleep, and psychosocial supportive-care questions were added after primary-source and duplication checks. None is evidence of tumor control.

• MS-N049 — Music therapy compared with CBT for anxiety in cancer survivors
• MS-N050 — Acupuncture compared with CBT-I for insomnia in cancer survivors
• MS-N051 — Tai Chi Chih compared with CBT-I for insomnia after breast cancer
• MS-N052 — Morning bright light for fatigue during breast-cancer chemotherapy
• MS-N053 — Expressive writing for symptoms and physical quality of life in renal cell carcinoma
• MS-N054 — Mindfulness-based programs for fatigue after breast cancer
• MS-N055 — Yoga during radiotherapy for breast-cancer quality of life
• MS-N056 — Progressive muscle relaxation plus guided imagery for anxiety during chemotherapy
• MS-N057 — Dignity therapy for distress near the end of life
• MS-N058 — Meaning-centered psychotherapy in advanced cancer

New evidence records · October 18, 2026

Ten supportive-care records were added. These additions include positive, mixed and negative primary outcomes; none tested tumor response, recurrence or survival.

• Acupuncture for fatigue after breast-cancer chemotherapy — promising but inconsistent
• Acupuncture for chemotherapy neuropathy — mixed; 2026 primary endpoint negative
• Acupuncture for chronic radiation dry mouth — positive versus oral hygiene; sham contrast time-dependent
• Acupuncture for chronic survivor pain — pragmatic benefit
• Electroacupuncture for hot flashes — promising phase II evidence
• P6 wristbands for chemotherapy nausea — no clear specific benefit
• Reflexology in advanced breast cancer — limited symptom/function signals
• Oral cryotherapy for mucositis prevention — regimen-specific support
• Scalp cooling for chemotherapy hair loss — effective for some regimens
• Frozen gloves and socks for taxane neuropathy — 2026 primary endpoint negative

See the dated Evidence Updates log →